These findings raise the question as to whether reducing monocyte infiltration by targeting the CCL2–CCR2 axis is a viable option for treating murine PDGFB–GBM, considering that 80% of the TAMs in this subtype are of monocyte origin. This evidence concerns the gene CCR2 and glioblastoma.